MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

MC

544.7

+0.68%↑

SANES

8.746

-0.64%↓

SAF

305.9

+0.43%↑

BBVA

16.405

-0.85%↓

BNP

76.9

-2.01%↓

Search

Grifols SA

Aperta

SettoreFinanza

12.62 -1.79

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.535

Massimo

12.83

Metriche Chiave

By Trading Economics

Entrata

57M

117M

Vendite

-85M

1.9B

P/E

Media del settore

28.011

28.015

EPS

0.19

Rendimento da dividendi

1.22

Margine di Profitto

6.19

Dipendenti

23,833

EBITDA

-135M

347M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+8.61% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.22%

3.82%

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.6B

7.4B

Apertura precedente

14.41

Chiusura precedente

12.62

Notizie sul Sentiment di mercato

By Acuity

50%

50%

190 / 530 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Grifols SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2025, 17:19 UTC

Acquisizioni, Fusioni, Takeovers

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 apr 2025, 13:02 UTC

Acquisizioni, Fusioni, Takeovers

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 apr 2025, 10:13 UTC

Acquisizioni, Fusioni, Takeovers

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

28 lug 2025, 10:51 UTC

Discorsi di Mercato

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

15 apr 2025, 09:55 UTC

Discorsi di Mercato

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 apr 2025, 09:27 UTC

Azioni calde

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Confronto tra pari

Modifica del prezzo

Grifols SA Previsione

Obiettivo di Prezzo

By TipRanks

8.61% in crescita

Previsioni per 12 mesi

Media 13.5 EUR  8.61%

Alto 15 EUR

Basso 12 EUR

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Grifols SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 8.566Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

190 / 530 Classifica in Finanza

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
help-icon Live chat